June Y. Hou, MD

Expertise in: 
Cancer Care, Gynecologic Cancers, Gynecologic Oncology
Board Certifications: 
Obstetrics and Gynecology, Hospice and Palliative Medicine
Accepting New Patients
Profile Headshot

Overview

june_hou_md_-_gynecologic_oncologist_at_columbiadoctors

Dr. June Y. Hou received her undergraduate degree at Yale College with Honors, and completed medical school at Georgetown University School of Medicine. After completing her residency training at Yale New Haven Hospital, she pursued a gynecologic oncology fellowship at Albert Einstein College of Medicine, Montefiore Medical Center. She is board certified in Obstetrics and Gynecology, Gynecologic Oncology, and Palliative Medicine.

She joins the faculty at Columbia University Medical Center with a research interest in early phase clinical trials, and quality of life measures in patients undergoing clinical trials for gynecologic malignancies. A past recipient of a career development grant focusing on molecular pathogenesis of ovarian cancer and rare uterine cancers, Dr. Hou has given multiple nationally-recognized presentations based on her work, and has lead numerous clinical trials. Clinically, Dr. Hou is certified in minimally invasive surgery, including robotic-assisted surgery. Her expertise includes chemotherapeutics and complex pelvic surgeries. Her goal is to provide compassionate and individualized care to all women with pre-malignant or gynecological cancers.

Areas of Expertise / Conditions Treated

  • Cervical Cancer
  • Cervical Dysplasia
  • Da Vinci Robotic Surgery
  • Female Pelvic Surgery
  • Gynecologic Cancer
  • Hospice and Palliative Medicine
  • Human Papillomavirus (HPV)
  • Laparoscopic Gynecologic Surgery
  • Ovarian Cancer
  • Ovarian Cancer Genetic Susceptibility
  • Ovarian Cyst
  • Robotic Gynecologic Surgery
  • Uterine Cancer
  • Vaginal Cancer
  • Vulvar Cancer

Academic Appointments

  • Assistant Professor of Obstetrics & Gynecology at CUMC

Administrative Titles

  • Co-Director, Hereditary Breast and Ovarian Cancer Program

Hospital Affiliations

  • NewYork-Presbyterian / Columbia University Irving Medical Center

Languages

  • Chinese - Mandarin

Gender

  • Female

Schedule an Appointment

Phone Appointments

New and Existing Patients:

Connect Patient Portal

For existing patients, login to make an appointment, view documentation or contact your care provider.

Connect Sign In

Location(s)

CUMC/Herbert Irving Pavilion
161 Fort Washington Avenue
New York, NY 10032
Primary
Orangeburg, NY Office
516 Route 303
Orangeburg, NY 10962

Insurance Accepted

Aetna

  • EPO
  • HMO
  • Medicare Managed Care
  • NYP Employee Plan
  • NY Signature
  • POS
  • PPO
  • Signature Administrators
  • Student Health

Affinity

  • Essential Plan
  • Medicaid Managed Care

AgeWell

  • Medicare Managed Care
  • Special Needs Plan

Amida Care

  • Special Needs Plan

Capital District Physician Health Plan

  • Capital District Physician Health Plan

Cigna

  • EPO
  • Great West
  • HMO
  • POS
  • PPO

Emblem/GHI

  • Medicare Managed Care
  • PPO

Emblem/HIP

  • ConnectiCare
  • EPO
  • Essential Plan
  • HMO
  • Medicaid Managed Care
  • Medicare Managed Care
  • POS
  • PPO
  • Select Care (Exchange)
  • Vytra

Empire Blue Cross Blue Shield

  • EPO
  • Medicare Managed Care
  • PPO

Empire Blue Cross Blue Shield HealthPlus

  • Child/Family Health Plus
  • Essential Plan
  • Medicaid Managed Care

Fidelis Care

  • Child/Family Health Plus
  • Medicaid Managed Care
  • Medicare Managed Care

Healthfirst

  • Child/Family Health Plus
  • Leaf (Exchange)
  • Medicaid Managed Care
  • Medicare Managed Care

Local 1199

  • Local 1199

MagnaCare

  • MagnaCare

Multiplan

  • Multiplan

MVP Health Care

  • Child/Family Health Plus
  • Essential Plan
  • HMO
  • Medicaid Managed Care

Oxford Health Plans

  • Freedom
  • Liberty

UnitedHealthcare

  • Columbia University Employee Plan
  • Compass (Exchange)
  • HMO
  • Medicaid (Community Plan)
  • Medicare Managed Care
  • POS
  • PPO

VNSNY CHOICE

  • Medicare Managed Care
  • SelectHealth
  • Special Needs Plan

WellCare

  • Medicaid Managed Care
  • Medicare Managed Care

*Please contact the provider’s office directly to verify that your particular insurance is accepted.

Credentials & Experience

Education & Training

  • MD, 2003 Georgetown University School of Medcine
  • Residency: Yale-New Haven Hospital
  • Fellowship: Albert Einstein / Montefiore Medical Center

Board Certifications

  • Obstetrics and Gynecology
  • Hospice and Palliative Medicine

Honors & Awards

National Faculty Award, American College of Obstetricians and Gynecologists, 2019

Research

Grants

ARANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERAPY WITH TSR-042 AND NIRAPARIB VERSUS STANDARD OF CARE PLATINUM-BASED THERAPY AS FIRST-LINE TREATMENT OF STAGE III OR IV NONMUCINOUS EPITHELIAL OVARIAN CANCER (P&S Industry Clinical Trial)

Aug 8 2019 - Aug 8 2024

SPL-006: AN OPEN LABEL PHASE 1 TRIAL OF SAFETY AND EFFICAY OF DIALY SUBCUTANEOUS SPL-108 INJECTIONS WHEN USED IN COMBINATION WITH PACLITAXEL IN PATIENTS WITH PLATINUM RESISTANT CD44+ ADVANCED OVARIAN EPITHELIAL CANCER (P&S Industry Clinical Trial)

Oct 18 2018 - Oct 18 2023

APHASE 1 STUDY OF SY-1365, A SELECTIVE CDK7 INHIBITOR, IN ADULT PATIENTS WITH ADVANCED SOLID TUMORS (P&S Industry Clinical Trial)

Oct 4 2018 - Oct 4 2023

A PHASE 1/2 STUDY OF REGN4018 ADMINISTERED ALONE OR IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH PLATINUM-RESISTANT OVARIAN CANCER (P&S Industry Clinical Trial)

Aug 13 2018 - Aug 13 2023

TRANSLATIONAL STUDIES UTILIZING SAMPLES FROM OVARIAN CANCER PATIENTS AT REGENERON PHARMACEUTICALS. (P&S Industry Clinical Trial)

Jun 14 2018 - Jun 14 2023

APHASE 1 DOSE ESCALATION AND COHORT EXPANSION STUDY OF TSR-042, AN ANTI-PD-1 MONOCLONAL ANTIBODY, IN PATIENTS WITH ADVANCED SOLID TUMORS (P&S Industry Clinical Trial)

Jun 1 2017 - Jun 30 2022

BREAST CANCER ACCESS TO CARE AND DISPARITIES RESEARCH PROGRAM (Private)

Jan 1 2018 - Dec 31 2018

SGNTV-002:OPEN LABEL PHASE 2 STUDY OF TISOTUMAB VEDOTIN FOR PATIENTS WITH PLATINUM RESISTANT OVARIAN CANCER WITH A SAFETY RUN-IN DOSE DENSE REGIMEN (P&S Industry Clinical Trial)

May 15 2019 - Jun 30 1999